GOSERELIN 3.6mg (Zoladex®)

Clinical Indication

Breast cancer

Comments

Zoladex 3.6mg implant is the only licensed product for breast cancer

Local guidance

To be included in the primary care enhanced service for administration

Date of classification

May 2016

Yellow

Medicines initiated or recommended by a specialist service for prescribing in primary care which do not require initiation or ongoing oversight by the specialist. There are no specific paperwork requirements between provider organisations and a verbal request may be acceptable through advice and guidance as long enough information is provided so that the transfer of care is safe.